<<The "obviously" is not obvious to me. >>
But, it is to me.
Partner requested additional trials (90 months safety in primate, and two in human TII diabetic) before it will consider license of the oral insulin? Why will they do that?
Also, who own this company? Potential insulin partner or shareholder? Do you not think that we DESERVE at least small note on ongoing and completed insulin trials!
IMW, main concern should be on:
- place on mode of the insulin absorption in GI system,
- bioavailable and action at fasting and/or mealtime
- condition for longer systemic insulin action
From recent presentation:
<< One study entitled "Gastric Absorption of Oral Insulin in Rats" demonstrated that oral insulin could be absorbed through the stomach. This pharmacokinetic study was conducted to determine systemic sites of insulin absorption after oral coadministration of an EMISPHERE(R) delivery agent. The next research steps for this study include examination of other sites of absorption along the gastrointestinal tract. (Abstract # R6142) >>
It is one thing if you want absorption in stomach-colon, and other at intestine. Different formulation?
I am not saying that their technology does not work. Their old heparin formulation show therapeutic level was achieved. But, one needs perfection with oral insulin, and this technology ask for time, source, work, … and bit of the luck here and there.
Miljenko |
